Daizo Kishino

787 total citations
39 papers, 555 citations indexed

About

Daizo Kishino is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Daizo Kishino has authored 39 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Daizo Kishino's work include Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (15 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Daizo Kishino is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (15 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Daizo Kishino collaborates with scholars based in Japan and United States. Daizo Kishino's co-authors include Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura, Daijiro Harada, Eiki Ichihara, Shinobu Hosokawa, Yoshihiko Segawa, Koji Inoue, Mitsune Tanimoto and Naohiro Oda and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Daizo Kishino

38 papers receiving 550 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daizo Kishino Japan 12 367 353 124 54 47 39 555
Kensuke Nakazawa Japan 8 279 0.8× 273 0.8× 98 0.8× 89 1.6× 43 0.9× 30 489
Shinichiro Shimamatsu Japan 12 352 1.0× 277 0.8× 175 1.4× 29 0.5× 22 0.5× 40 580
Samir Darwish Italy 12 250 0.7× 311 0.9× 116 0.9× 46 0.9× 30 0.6× 17 441
S. Nagel Germany 10 239 0.7× 207 0.6× 76 0.6× 50 0.9× 14 0.3× 29 421
Ryo Ko Japan 12 299 0.8× 392 1.1× 122 1.0× 31 0.6× 16 0.3× 60 547
Carol A. Sherman United States 13 317 0.9× 377 1.1× 125 1.0× 64 1.2× 24 0.5× 28 554
Jiang Fan China 11 120 0.3× 223 0.6× 83 0.7× 38 0.7× 53 1.1× 42 454
Akihisa Sutani Japan 11 386 1.1× 511 1.4× 157 1.3× 34 0.6× 19 0.4× 34 643
Xiaoqing Liu China 13 350 1.0× 487 1.4× 136 1.1× 33 0.6× 21 0.4× 51 622
Ken Saijo Japan 12 232 0.6× 133 0.4× 203 1.6× 39 0.7× 16 0.3× 47 530

Countries citing papers authored by Daizo Kishino

Since Specialization
Citations

This map shows the geographic impact of Daizo Kishino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daizo Kishino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daizo Kishino more than expected).

Fields of papers citing papers by Daizo Kishino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daizo Kishino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daizo Kishino. The network helps show where Daizo Kishino may publish in the future.

Co-authorship network of co-authors of Daizo Kishino

This figure shows the co-authorship network connecting the top 25 collaborators of Daizo Kishino. A scholar is included among the top collaborators of Daizo Kishino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daizo Kishino. Daizo Kishino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sakamoto, Shuichi, Kayo Nakamura, Soichiro Fushimi, et al.. (2024). Two autopsied gastric cancer cases of rare drug-induced pneumonia associated with nivolumab plus S-1 and oxaliplatin: a case report. Journal of Gastrointestinal Oncology. 15(1). 491–499.
2.
Kubo, Toshio, Eiki Ichihara, Daijiro Harada, et al.. (2023). Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer. Respiratory Investigation. 61(5). 643–650. 3 indexed citations
3.
4.
Nakamura, Kayo, Daizo Kishino, Shuko Mashimo, et al.. (2023). Mycobacterium shinjukuense infection successfully treated with clarithromycin, rifampicin, and ethambutol. Respiratory Medicine Case Reports. 45. 101894–101894. 2 indexed citations
5.
Ichihara, Eiki, Toshihide Yokoyama, Koji Inoue, et al.. (2022). The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study. Cancers. 14(24). 6184–6184. 4 indexed citations
6.
Ichihara, Eiki, Toshihide Yokoyama, Koji Inoue, et al.. (2022). More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance. Journal of Cancer Research and Clinical Oncology. 149(8). 4933–4938. 2 indexed citations
7.
Ochi, Nobuaki, Eiki Ichihara, Nagio Takigawa, et al.. (2021). The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression. European Journal of Cancer. 149. 73–81. 43 indexed citations
8.
Hara, Naofumi, Eiki Ichihara, Daijiro Harada, et al.. (2021). Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology. 147(12). 3749–3755. 7 indexed citations
9.
Ichihara, Eiki, Daijiro Harada, Koji Inoue, et al.. (2020). Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. Cancer Immunology Immunotherapy. 70(1). 101–106. 28 indexed citations
10.
Kano, Hirohisa, Eiki Ichihara, Daijiro Harada, et al.. (2020). Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status. Cancer Science. 111(10). 3739–3746. 18 indexed citations
11.
Ichihara, Eiki, Daijiro Harada, Koji Inoue, et al.. (2019). The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer. 139. 140–145. 74 indexed citations
12.
13.
Oda, Naohiro, Eiki Ichihara, Katsuyuki Hotta, et al.. (2016). Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. Clinical Lung Cancer. 18(2). 241–244. 8 indexed citations
14.
15.
Chikamori, Kenichi, Daizo Kishino, Nagio Takigawa, et al.. (2008). A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. Lung Cancer. 65(1). 74–79. 11 indexed citations
16.
Tabata, Masahiro, Toshiyuki Kozuki, Hiroshi Ueoka, et al.. (2006). A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemotherapy and Pharmacology. 60(1). 53–59. 2 indexed citations
17.
Takigawa, Nagio, Mikiko Ida, Yoshihiko Segawa, et al.. (2004). Expression of cyclooxygenase-2, Fas and Fas ligand in pulmonary adenocarcinoma and atypical adenomatous hyperplasia.. PubMed. 23(6D). 5069–73. 4 indexed citations
18.
Takigawa, Nagio, Yoshihiko Segawa, Daizo Kishino, et al.. (2004). Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemotherapy and Pharmacology. 54(3). 230–6. 17 indexed citations
19.
Takigawa, Nagio, Yoshihiko Segawa, Toshiaki Saeki, et al.. (2000). Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: Radiation-induced lung toxicity. International Journal of Radiation Oncology*Biology*Physics. 48(3). 751–755. 65 indexed citations
20.
Takigawa, Nagio, Yoshihiko Segawa, Masao Nakata, et al.. (1999). Clinical investigation of atypical adenomatous hyperplasia of the lung. Lung Cancer. 25(2). 115–121. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kensuke Nakazawa Breakdown of academic impact, for papers by Shinichiro Shimamatsu Breakdown of academic impact, for papers by Samir Darwish Breakdown of academic impact, for papers by S. Nagel Breakdown of academic impact, for papers by Ryo Ko Breakdown of academic impact, for papers by Carol A. Sherman Breakdown of academic impact, for papers by Jiang Fan Breakdown of academic impact, for papers by Akihisa Sutani Breakdown of academic impact, for papers by Xiaoqing Liu Breakdown of academic impact, for papers by Ken Saijo
Rankless by CCL
2026